tenofovir + abacavir + lamivudine

This drug is a fixed-dose oral combination of three antiretroviral agents: **tenofovir**, **abacavir**, and **lamivudine**. All three are nucleos(t)ide reverse transcriptase inhibitors (NRTIs). Tenofovir is a nucleotide analog (acyclic analog of adenosine monophosphate); abacavir and lamivudine are nucleoside analogs (guanosine and cytidine, respectively). All three drugs inhibit HIV-1 reverse transcriptase, leading to premature termination of the viral DNA chain and inhibition of HIV replication. This combination would be used as part of antiretroviral therapy to treat HIV/AIDS. There is no widely recognized brand name or unique commercial formulation for this exact combination. Each individual component is approved for HIV-1 infection, and various combinations are available in practice.